User:Michael Lartey/Sandbox: Difference between revisions

From Proteopedia
Jump to navigationJump to search
← Older editNewer edit →
No edit summary
No edit summary
Line 12: Line 12:
Herpes simplex virus thymidine kinase (TKHSV1) is a homodimeric α/β- protein comprising of five β-sheets and twelve α-helices per unit. Each unit also has a sulfate ion. It has a two-fold axis. At the interphase are three helices from each monomer where non-polar side chains interact.  [[Image:Chain connectivity in TK HSV1.png|thumb]] TKHSV1 is less specific than the human analog; it catalyzes the phosphorylation of pyrimidines, purines and a wide range of ribose analogs. The broad specificity of TKHSV1 has found a lot of therapeutic use in virally directed enzyme prodrug therapy in the treatment of herpes and cancer. The enzyme phosphorylates a non-toxic prodrug to a toxic form that inhibits viral replication. Drugs such as acyclovir for herpes treatment, AZT for HIV treatment and gancyclovir for cancer treatment work in this manner.  The drawback with these therapeutic procedures is the poor binding of the enzyme to the drug. A higher dosage is required and this leads to toxicity.  
Herpes simplex virus thymidine kinase (TKHSV1) is a homodimeric α/β- protein comprising of five β-sheets and twelve α-helices per unit. Each unit also has a sulfate ion. It has a two-fold axis. At the interphase are three helices from each monomer where non-polar side chains interact.  [[Image:Chain connectivity in TK HSV1.png|thumb]] TKHSV1 is less specific than the human analog; it catalyzes the phosphorylation of pyrimidines, purines and a wide range of ribose analogs. The broad specificity of TKHSV1 has found a lot of therapeutic use in virally directed enzyme prodrug therapy in the treatment of herpes and cancer. The enzyme phosphorylates a non-toxic prodrug to a toxic form that inhibits viral replication. Drugs such as acyclovir for herpes treatment, AZT for HIV treatment and gancyclovir for cancer treatment work in this manner.  The drawback with these therapeutic procedures is the poor binding of the enzyme to the drug. A higher dosage is required and this leads to toxicity.  


 
[[Image:Conservation.png|thumb|left]]
'''Catalysis and Ligand Binding'''
'''Catalysis and Ligand Binding'''


Line 20: Line 20:
[[Image:Surface charge distribution.png|thumb]]
[[Image:Surface charge distribution.png|thumb]]


[[Image:Conservation.png|thumb|left]]
 


'''References'''
'''References'''
Retrieved from "https://proteopedia.org/User:Michael_Lartey/Sandbox"